Financial Performance - The company's operating revenue for the first half of 2021 was ¥195,297,816.23, representing a 36.50% increase compared to ¥143,079,710.90 in the same period last year[19]. - The net profit attributable to shareholders was ¥26,657,994.57, up 38.21% from ¥19,288,313.54 year-on-year[19]. - The net profit after deducting non-recurring gains and losses was ¥22,474,953.20, reflecting a 48.28% increase from ¥15,157,070.55 in the previous year[19]. - The net cash flow from operating activities was ¥30,694,740.20, an increase of 81.02% compared to ¥16,956,958.62 in the same period last year[19]. - Basic earnings per share rose to ¥0.12, a 33.33% increase from ¥0.09 in the previous year[19]. - The company achieved a revenue of 195.30 million yuan in the first half of 2021, representing a year-on-year growth of 36.50%[30]. - The net profit attributable to shareholders was 26.66 million yuan, an increase of 38.21% compared to the previous year[30]. - The company reported a significant increase in revenue, achieving a total of 500 million CNY for the first half of 2021, representing a 20% year-over-year growth[68]. - The net profit for the first half of 2021 was CNY 27,759,533.88, an increase of 37.5% compared to CNY 20,170,486.61 in the same period of 2020[133]. - Operating profit rose to CNY 30,426,248.27, up 28.4% from CNY 23,736,168.45 year-on-year[133]. Assets and Liabilities - Total assets at the end of the reporting period were ¥981,483,411.97, a 7.17% increase from ¥915,812,091.29 at the end of the previous year[19]. - The total assets at the end of the reporting period were ¥980,000,000, with cash and cash equivalents amounting to ¥249,149,973.17, representing 25.39% of total assets[46]. - The company's total assets increased to CNY 985,944,054.77, compared to CNY 916,054,167.26 at the end of the previous period, reflecting a growth of 7.6%[126]. - The total liabilities increased to CNY 199,415,974.65 from CNY 150,662,349.53, reflecting a rise of approximately 32.3%[121]. - The company's total liabilities rose to CNY 198,359,473.45, up from CNY 147,488,693.92, indicating a 34.5% increase[126]. - The company's cash and cash equivalents were CNY 249,149,973.17 as of June 30, 2021, compared to CNY 242,007,755.38 at the end of 2020, showing a slight increase of about 2.4%[119]. - The company's equity attributable to shareholders reached CNY 779,614,748.56, up from CNY 761,707,349.51, indicating an increase of approximately 2.5%[122]. - The company's total equity totaled CNY 787,584,581.32, a slight increase from CNY 768,565,473.34, showing a growth of 2.1%[126]. Operational Strategy - The company focuses on the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, which are essential pharmaceutical excipients[30]. - The company has established a centralized procurement model to manage production materials and reduce costs effectively[28]. - The company maintains a production model based on sales forecasts, ensuring a balance between production and inventory levels[28]. - The company emphasizes innovation in marketing strategies to enhance brand recognition and expand market share[33]. - The company invests in R&D to develop new products and improve production processes, holding several patents for advanced technologies[34]. - The company aims to become a leading pharmaceutical technology service platform in China by enhancing R&D investment and innovation capabilities[36]. - The company has established strong partnerships with major pharmaceutical enterprises, ensuring a broad customer base across over 30 provinces in China[33]. Market Performance - Domestic sales accounted for 97.18% of total revenue, amounting to ¥189,781,627.70, with a year-on-year growth of 32.68%[43]. - The company reported a significant increase in foreign sales, which rose to ¥5,516,188.53, marking a staggering growth of 12,380.60% compared to the previous year[43]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[73]. Risks and Challenges - The company faces regulatory risks due to the lack of a comprehensive management system in the pharmaceutical capsule industry, which may lead to market competition challenges and product quality discrepancies[53]. - The price of gelatin, the main raw material for capsules, is subject to significant fluctuations, which could impact procurement costs and gross margins; the company plans to optimize procurement processes and conduct market research to mitigate this risk[53]. - The company anticipates risks related to product price reductions due to ongoing policies such as consistency evaluation for generic drugs and centralized procurement, which may lead to decreased profit margins in the pharmaceutical industry[54]. - The company is expanding its human resources management system to address potential talent shortages as it scales operations, focusing on attracting and retaining high-quality professionals[54]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company did not distribute cash dividends or issue bonus shares for the half-year period, nor did it convert capital reserves into share capital[59]. - The largest shareholder, Yu Chunming, holds 38.05% of the shares, totaling 81,287,725 shares, with 43,500,000 shares pledged[106]. - The second-largest shareholder, Yu Chaobiao, holds 3.46% of the shares, totaling 7,395,000 shares, with 1,848,750 shares released from restrictions[106]. - The company has a total of 10 major shareholders, with the top two controlling over 41.51% of the total shares[106]. Compliance and Governance - The company has committed to maintaining transparency and compliance with regulatory requirements, ensuring no violations occurred during the reporting period[72]. - The financial report for the first half of 2021 has not been audited yet, which is standard practice for this reporting period[75]. - The company has not engaged in any significant litigation or arbitration matters during this period[76]. - The company has no significant related party transactions during the reporting period[78]. - The company has not initiated any poverty alleviation or rural revitalization efforts during the reporting period[64]. Financial Management - The company reported a total of 9,800,000 CNY in entrusted financial management, with an occurrence amount of 200,000 CNY[90]. - The company has no overdue receivables or impairment provisions related to entrusted financial management[92]. - The company has no major contracts or guarantees in place during the reporting period[88]. - The company has not engaged in any asset or equity acquisitions or sales during the reporting period[79]. - The company has no significant daily operational contracts during the reporting period[93]. - The company has no major related party debts or financial transactions[81]. - The company has not experienced any significant changes in shareholding or shareholder structure during the reporting period[96]. - The company has no major matters requiring explanation during the reporting period[94]. - The company has no significant joint external investments during the reporting period[80]. Accounting Policies - The financial statements prepared by the company comply with the requirements of the accounting standards, reflecting the financial position, operating results, and cash flows accurately[159]. - The company uses Renminbi as its functional currency for domestic operations, while its overseas subsidiary uses the currency of its primary economic environment[162]. - The company follows specific accounting policies for financial instrument impairment, fixed asset depreciation, intangible asset amortization, and revenue recognition[158]. - The company consolidates all subsidiaries under its control in the consolidated financial statements, based on the financial statements of the parent and its subsidiaries[164]. - The company recognizes goodwill when the acquisition cost exceeds the fair value of identifiable net assets acquired in a business combination[163].

Group 1: Event Details - The company will participate in the "2021 Anhui Listed Companies Investor Collective Reception Day" [2] - The event is organized by the Anhui Securities Regulatory Bureau, Anhui Listed Companies Association, and Shenzhen Panorama Network Co., Ltd. [2] - The event will be held online on May 18, 2021, from 14:00 to 17:30 [2] Group 2: Participants - Attendees include the company's director, deputy general manager, and board secretary, Mr. Xiang Xianli [2] - The financial director, Ms. Dong Xue, and securities affairs representative, Ms. Wang Baozhen, will also be present [2] Group 3: Investor Engagement - The company aims to enhance communication with investors and improve transparency and governance [2] - Investors are encouraged to actively participate in the event [2]

Financial Performance - The company's operating revenue for Q1 2021 was ¥104,095,453.39, representing a 48.14% increase compared to ¥70,266,086.21 in the same period last year[7]. - The net profit attributable to shareholders was ¥10,799,475.10, up 19.76% from ¥9,017,259.94 year-on-year[7]. - The net profit after deducting non-recurring gains and losses was ¥8,727,524.14, reflecting a 16.93% increase from ¥7,463,846.01 in the previous year[7]. - The company reported a net profit margin improvement, with undistributed profits rising to CNY 341,651,516.17 from CNY 330,852,041.07, an increase of about 3.5%[47]. - Total comprehensive income for the first quarter was CNY 10,261,941.56, compared to CNY 8,704,549.13, marking an increase of approximately 17.9%[55]. - Operating profit for the first quarter was CNY 11,590,470.33, compared to CNY 10,316,722.66 in the previous period, showing an increase of about 12.3%[54]. - Net profit for the first quarter reached CNY 10,244,482.70, up from CNY 8,704,549.13, indicating a growth of approximately 17.7% year-over-year[54]. Cash Flow - The net cash flow from operating activities decreased by 33.52% to ¥14,824,838.69 from ¥22,298,376.00 in the same period last year[7]. - Net cash flow from operating activities decreased by CNY 7,473,500, a decline of 33.52% year-on-year, mainly due to increased cash payments for goods and services[30]. - Net cash flow from investing activities decreased by CNY 22,639,300, a decline of 164.54% year-on-year, primarily due to increased cash payments for the purchase of fixed assets, intangible assets, and other long-term assets[30]. - Net cash flow from financing activities increased by CNY 26,345,900, a growth rate of 48,972.63% year-on-year, mainly due to an increase in borrowings[30]. - The net increase in cash and cash equivalents decreased by CNY 3,756,200, a decline of 44.26% year-on-year, primarily due to reduced net cash flow from operating and investing activities despite increased financing cash flow[30]. - Cash inflow from operating activities amounted to CNY 78,514,426.76, an increase from CNY 60,921,525.98 in the previous period, reflecting a growth of approximately 28.8%[61]. - Cash outflow for the acquisition of fixed assets was CNY 36,355,474.13, compared to CNY 9,849,680.39 in the previous period, indicating increased capital expenditures[66]. Assets and Liabilities - Total assets at the end of the reporting period were ¥973,707,066.87, a 6.32% increase from ¥915,812,091.29 at the end of the previous year[7]. - The company's total liabilities reached CNY 198,295,383.55, compared to CNY 150,662,349.53 in the previous period, marking an increase of about 31.6%[46]. - Total liabilities increased by 325.80% to ¥651,600.00, mainly due to an increase in short-term borrowings[20]. - Non-current liabilities increased to CNY 56,778,836.53 from CNY 35,921,906.76, reflecting a rise of approximately 58%[50]. - Long-term borrowings increased significantly to CNY 33,991,846.98 from CNY 13,864,052.92, representing an increase of approximately 145%[50]. - The company's equity attributable to shareholders reached CNY 772,520,791.70, compared to CNY 761,707,349.51 in the previous period, reflecting a growth of about 1.1%[47]. Operational Costs and Expenses - The company reported a 71.43% increase in operating costs, amounting to ¥7,628,000.00, primarily due to increased sales and the inclusion of shipping costs in operating expenses[22]. - The company experienced a 506.82% increase in taxes and surcharges, totaling ¥626,000.00, due to the expiration of tax relief policies from the previous year[23]. - The company incurred a tax expense of CNY 1,337,857.63, slightly down from CNY 1,379,726.97 in the previous period[54]. - The company's R&D expenses increased by 35.37% to ¥341,130.00, driven by increased investment in R&D projects[24]. - Research and development expenses increased to CNY 3,602,953.61 from CNY 2,661,619.82, reflecting a rise of about 35.3%[53]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 14,546, with the largest shareholder holding 38.05% of the shares[11]. - Basic and diluted earnings per share were both CNY 0.07, an increase from CNY 0.06 in the same period last year[55].

Financial Performance - The company's operating revenue for 2020 was CNY 319,426,287.89, a decrease of 1.88% compared to CNY 325,557,296.04 in 2019[15] - The net profit attributable to shareholders for 2020 was CNY 45,255,710.15, representing a 15.65% increase from CNY 39,130,702.48 in 2019[15] - The net cash flow from operating activities increased by 20.53% to CNY 62,711,557.61 in 2020, up from CNY 52,028,243.84 in 2019[15] - Basic earnings per share for 2020 were CNY 0.31, an increase of 14.81% from CNY 0.27 in 2019[15] - Total assets at the end of 2020 were CNY 915,812,091.29, a 10.10% increase from CNY 831,803,641.17 at the end of 2019[15] - The company's weighted average return on equity for 2020 was 6.10%, up from 5.53% in 2019[15] - The net profit after deducting non-recurring gains and losses for 2020 was CNY 36,442,844.58, a 14.69% increase from CNY 31,775,849.66 in 2019[15] - The company's net assets attributable to shareholders at the end of 2020 were CNY 761,707,349.51, a 5.12% increase from CNY 724,606,241.80 at the end of 2019[15] Dividend Distribution - The company plans to distribute a cash dividend of CNY 0.60 per 10 shares to all shareholders, based on a total of 147,339,000 shares[4] - The cash dividend payout ratio for 2020 was 19.53% of the net profit attributable to shareholders[93] - The cash dividend payout ratio for 2019 was 21.04% of the net profit attributable to shareholders[93] - The cash dividend payout ratio for 2018 was 20.48% of the net profit attributable to shareholders[93] - The total distributable profit for 2020 was RMB 330,852,041.07[93] Market and Industry Trends - The company plans to enhance its marketing model and strengthen market development efforts in response to changes in the pharmaceutical industry[28] - The pharmaceutical industry is expected to see increased demand for standardized and specialized hollow capsules due to evolving regulatory requirements[27] - The company is focusing on continuous technological innovation and product quality assurance to maintain a competitive edge in the industry[28] - The company is actively pursuing a new intelligent manufacturing model for hollow capsules as part of its ongoing projects[29] Research and Development - The company has invested in R&D, resulting in multiple patents and recognition for its innovative products, including the development of enteric-coated gelatin capsules[34] - The company has obtained 8 patent authorizations and filed for 8 additional patents during the year[58] - Research and development expenses amounted to ¥9,348,494.75, a decrease of 26.82% compared to the previous year[59] - The company is committed to increasing R&D investment to enhance its competitive advantage in the pharmaceutical technology service sector[35] - New product development includes seven national invention patents related to various types of capsules, enhancing the company's product portfolio[163] Operational Efficiency - The company has established a comprehensive procurement, production, and sales system to optimize operational efficiency and cost control[24] - The company has established a comprehensive quality management system, achieving certifications such as ISO9002, ISO14001, and ISO45001[31] - The company has adopted advanced production technologies, including non-sterile production processes, to improve efficiency and product quality[31] - The company has a strong brand reputation, recognized as one of the earliest manufacturers of pharmaceutical capsules in China, with its products awarded various accolades[37] Shareholder Structure and Management - The total number of shareholders increased to 14,768 by the end of the reporting period, up from 14,546 at the end of the previous month[145] - The largest shareholder, Yu Chunming, holds 38.05% of the shares, totaling 56,060,500 shares, with 44,255,250 shares under lock-up[145] - The company’s capital increase was based on a ratio of 10 shares for every 7 shares, benefiting all shareholders[142] - The company has ensured that minority shareholders had opportunities to express their opinions and that their legal rights were protected[89] Compliance and Governance - The company has established a transparent information disclosure system, complying with the requirements of the China Securities Regulatory Commission[184] - The independent directors attended all board meetings and did not raise any objections to company matters during the reporting period[192] - The company has committed to compensating investors for losses incurred due to any violations recognized by the China Securities Regulatory Commission within 30 days[98] - There were no significant accounting errors that required retrospective restatement during the reporting period[102] Social Responsibility - The company engaged in social responsibility activities, donating 239,200 yuan to social welfare initiatives during the reporting period[128] - The company actively participated in social welfare activities, including blood donation drives and support for underprivileged workers[128] Future Outlook - The company has set a performance guidance for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion CNY[163] - The company is expanding its market presence, targeting a 25% increase in market share within the next two years[163] - The management team emphasizes a commitment to quality and innovation, aiming to maintain leadership in the pharmaceutical sector[163]

Financial Performance - Net profit attributable to shareholders was ¥14,334,166.20, representing a growth of 10.27% year-on-year[8]. - Operating revenue for the period was ¥72,031,468.35, a decrease of 10.45% compared to the same period last year[8]. - Basic earnings per share were ¥0.10, up by 11.11% from the previous year[8]. - The weighted average return on net assets was 1.93%, an increase of 0.11% compared to the previous year[8]. - The company reported a net profit for the same period of 2.12%, indicating a stable profitability level[26]. - The company achieved an operating profit of CNY 17,073,815.19, up from CNY 15,532,875.77, reflecting a growth of 9.9%[51]. - The total comprehensive income for the period was CNY 32,497,215.85, compared to CNY 30,120,997.42 in the previous period, marking an increase of 7.9%[54]. - The net profit for the third quarter of 2020 was CNY 35,015,796.01, an increase of 7.2% compared to CNY 32,674,206.11 in the same period last year[58]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥845,176,526.64, an increase of 1.61% compared to the end of the previous year[8]. - The company's current assets totaled CNY 548,188,965.58, slightly down from CNY 559,861,489.71 in the previous year[36]. - Total liabilities decreased to CNY 91,337,657.33 from CNY 105,478,337.71, representing a reduction of approximately 13.4%[38]. - The equity attributable to shareholders increased to CNY 749,995,071.54 from CNY 724,606,241.80, showing a growth of about 3.5%[39]. - Total liabilities decreased to CNY 90,469,566.89 from CNY 103,838,676.70, a reduction of approximately 13%[42]. Cash Flow - The net cash flow from operating activities was ¥16,434,493.70, showing a slight increase of 1.20%[8]. - Cash flow from operating activities generated a net amount of CNY 33,391,452.32, compared to CNY 30,274,791.76 in the previous year, indicating an increase of 10.5%[62]. - The company reported cash and cash equivalents at the end of the period amounting to CNY 234,888,104.96, an increase from CNY 182,638,180.09 year-over-year[63]. - The net cash flow from investing activities increased by 31.8109 million yuan, a growth rate of 99.33%, mainly due to a decrease in the purchase of financial products during the period[18]. - The net cash flow from investing activities was CNY 439,452.72, a significant improvement from a negative CNY 32,988,861.30 in the same period last year[67]. Research and Development - R&D expenses decreased by 2.9614 million yuan, a decline of 31.84%, mainly due to reduced investment in R&D expenses during the period[17]. - Research and development expenses for Q3 2020 were CNY 1,901,476.18, down from CNY 2,629,362.68, indicating a decrease of approximately 27.7%[45]. - Investment in research and development is prioritized to drive long-term growth and innovation[26]. - Future investments are planned to enhance research and development capabilities, aiming for innovative product solutions[29]. Strategic Initiatives - The company plans to expand its market presence and enhance product offerings in the upcoming quarters[26]. - New product development initiatives are underway, focusing on innovative technologies to meet market demands[26]. - The company is exploring potential mergers and acquisitions to strengthen its competitive position in the industry[26]. - The company aims to enhance shareholder value through strategic initiatives and effective capital management[26]. Compliance and Governance - The company has no overdue commitments or securities investments during the reporting period[20][21]. - The company had no instances of non-compliance with external guarantees during the reporting period[31]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[32]. - The company has implemented new revenue and leasing standards starting January 1, 2020, affecting accounting policies[77]. - The third quarter report was not audited, indicating potential limitations in the reliability of the financial data presented[78].

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 143,079,710.90, a decrease of 8.51% compared to CNY 156,388,560.75 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was CNY 19,288,313.54, representing an increase of 4.85% from CNY 18,396,793.94 year-on-year[18]. - The total profit reached CNY 21,582,989.07, an increase of 5.24% year-on-year[37]. - The net profit excluding non-recurring gains and losses was CNY 15,157,070.55, a decline of 7.67% year-on-year[37]. - The company reported a net profit margin of 10.39% for the first half of the year[95]. - The company achieved a total profit of CNY 23,178,292.05 in the first half of 2020, up from CNY 22,153,759.15 in the same period of 2019, representing an increase of about 4.62%[143]. - The company reported a net loss of 7.37 million yuan for the first half of 2020, compared to a profit of 950,000 yuan in the same period last year[166]. Cash Flow and Liquidity - The net cash flow from operating activities increased by 20.82% to CNY 16,956,958.62, compared to CNY 14,035,348.80 in the previous year[18]. - The company's cash and cash equivalents decreased by 87.76% to ¥3,704,789.48 from ¥30,266,234.06, primarily due to the recovery of financial products in the previous period[42]. - The cash flow from financing activities resulted in a net outflow of -8,348,459.39 CNY, compared to -7,165,654.86 CNY in the previous period[152]. - The company is focusing on maintaining liquidity amid fluctuating cash flows from investment and financing activities[156]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 818,125,914.83, a decrease of 1.64% from CNY 831,803,641.17 at the end of the previous year[18]. - Total liabilities decreased to CNY 78,209,077.74 from CNY 105,478,337.71, marking a reduction of about 25.8%[131]. - The company's current assets totaled CNY 539,744,558.04, down from CNY 559,861,489.71 at the end of 2019, indicating a decline of approximately 3.99%[130]. - The total equity attributable to shareholders of the parent company increased to CNY 735,660,905.34 from CNY 724,606,241.80, showing a growth of approximately 1.5%[132]. Investment and Development - The company invested a total of ¥3,185.18 million in the "Intelligent Manufacturing New Model Project for Hollow Capsules" during the reporting period[39]. - The company is actively investing in new product development and technology upgrades, focusing on customized services for clients[31][32]. - The company has established a comprehensive quality management system, achieving certifications such as GMP and NSF, and has received FDA DMF registration for its products[29][32]. Market and Competition - The company has faced challenges due to increased market competition and policy impacts, leading to a decline in product sales prices and increased production costs[59]. - The company is expanding its market presence by enhancing its technological capabilities and collaborating with research institutions[32][30]. - The company anticipates continued pressure on traditional product margins due to policies like drug price negotiations and volume-based procurement, leading to potential product price reductions[69]. Risk Management - The company faced risks and has outlined measures to address them in the report[5]. - The company faces significant risks from policy regulation changes in the pharmaceutical industry, which may impact market competition and product quality[68]. - The price of gelatin, a key raw material for the company's products, has increased due to supply chain disruptions, affecting procurement costs and gross margins[69]. Shareholder Information - The total number of shares increased from 86,670,000 to 147,339,000, representing a 69.9% increase[107]. - The largest shareholder, Yu Chunming, holds 40.05% of the shares, totaling 59,007,000 shares[111]. - The total number of shareholders at the end of the reporting period was 16,680[111]. Corporate Governance - The semi-annual financial report was not audited, which may affect the reliability of the financial data presented[127]. - The company did not undergo any changes in its board of directors, supervisors, or senior management during the reporting period[123]. - The financial statements were approved by the board on August 17, 2020, and are based on the assumption of going concern[169]. Environmental and Social Responsibility - The company maintains a unified management approach to environmental protection, adhering to national regulations[97]. - The company has not initiated any poverty alleviation programs in the reporting year and has no plans for future initiatives[98][100].

Financial Performance - The company's revenue for Q1 2020 was ¥70,266,086.21, a decrease of 9.56% compared to ¥77,691,919.82 in the same period last year[8] - Net profit attributable to shareholders was ¥9,017,259.94, an increase of 2.68% from ¥8,781,777.06 year-on-year[8] - The company's operating revenue for the current period is ¥70,044,980.01, a decrease of 9.5% compared to ¥77,689,359.47 in the previous period[44] - The net profit for the current period is ¥9,400,337.32, representing an increase of 2.0% from ¥9,218,247.51 in the previous period[45] - Net profit for Q1 2020 was CNY 8,704,549.13, compared to CNY 8,362,616.62 in the same period last year, representing an increase of approximately 4.1%[41] Cash Flow - The net cash flow from operating activities increased by 229.25% to ¥22,298,376.00, compared to ¥6,772,566.91 in the previous year[8] - The net cash flow from operating activities for Q1 2020 was ¥26,918,214.27, a significant increase from ¥7,700,974.53 in the same period last year, representing a growth of approximately 249.5%[52] - Net cash flow from investing activities decreased by 66,061,700 yuan, a decline of 126.31%, mainly due to increased purchases of financial products compared to the same period last year[17] - The cash inflow from investment activities is ¥102,275,205.61, while cash outflow from investment activities is ¥116,034,464.67, resulting in a net cash flow of -¥13,759,259.06[50] - The total cash and cash equivalents at the end of Q1 2020 stood at ¥214,070,906.41, down from ¥250,488,908.30 at the end of the previous year, a decrease of approximately 14.5%[53] Assets and Liabilities - Total assets at the end of the reporting period were ¥847,486,343.22, reflecting a growth of 1.89% from ¥831,803,641.17 at the end of the previous year[8] - The total assets as of March 31, 2020, amounted to CNY 850,190,753.01, up from CNY 833,054,287.04 at the end of 2019[36] - The total current liabilities rose to CNY 88,143,291.51 from CNY 81,984,563.82, indicating an increase of approximately 7.3%[32] - The company's total liabilities increased to CNY 111,574,805.35 from CNY 103,838,676.70, indicating a rise of about 7.1%[37] - The total liabilities increased to CNY 112,456,490.63 from CNY 105,478,337.71, marking an increase of approximately 6.5%[32] Equity - The total equity attributable to shareholders of the parent company rose to CNY 738,615,947.66 from CNY 729,215,610.34, reflecting a growth of approximately 1.9%[37] - The company's equity remained stable at CNY 735,029,852.59, unchanged from the previous reporting period[32] - The total equity attributable to shareholders was ¥724,606,241.80, consistent with the previous year[56] Expenses - Total operating costs decreased to CNY 60,775,130.38 from CNY 67,568,441.79, with operating costs specifically dropping from CNY 51,515,105.12 to CNY 44,418,528.12[40] - Research and development expenses decreased to CNY 2,661,619.82 from CNY 3,395,750.64, a reduction of approximately 21.5%[40] - The company incurred sales expenses of ¥8,902,213.64, an increase of 19.8% from ¥7,434,710.53 in the previous period[44] Other Financial Metrics - The weighted average return on net assets was 1.24%, slightly down from 1.26% in the previous year[8] - The company has not reported any non-recurring gains or losses that would be classified as regular income[10] - The company reported a financial asset impairment loss of ¥1,250,078.96, compared to ¥1,091,664.48 in the previous period[45] - The company reported no derivative investments during the reporting period, indicating a conservative investment strategy[23] Governance and Compliance - There were no violations regarding external guarantees or non-operating fund occupation by controlling shareholders during the reporting period, reflecting sound governance practices[24][25] - The company has no overdue commitments from actual controllers, shareholders, related parties, acquirers, or other parties during the reporting period[18] - The company will implement the new revenue recognition standards starting January 1, 2020, as per the Ministry of Finance's requirements[60] - The first quarter report for 2020 was not audited[60]

Financial Performance - The company's operating revenue for 2019 was CNY 325,557,296.04, representing a 10.47% increase compared to CNY 294,709,587.46 in 2018[16]. - The net profit attributable to shareholders for 2019 was CNY 39,130,702.48, an increase of 8.80% from CNY 35,966,208.29 in 2018[16]. - The net profit after deducting non-recurring gains and losses was CNY 31,775,849.66, which is a 16.11% increase from CNY 27,367,955.00 in 2018[16]. - The net cash flow from operating activities increased by 89.03% to CNY 52,028,243.84 from CNY 27,523,879.86 in 2018[16]. - The total assets at the end of 2019 were CNY 831,803,641.17, a 6.64% increase from CNY 780,034,833.48 at the end of 2018[16]. - The net assets attributable to shareholders at the end of 2019 were CNY 724,606,241.80, up 4.63% from CNY 692,536,073.67 at the end of 2018[16]. - The basic earnings per share for 2019 was CNY 0.45, reflecting a 9.76% increase from CNY 0.41 in 2018[16]. - The weighted average return on equity for 2019 was 5.53%, slightly up from 5.30% in 2018[16]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion CNY for the year, representing a growth of 15% compared to the previous year[94]. - The company reported a revenue of 5,000 million yuan for the period, reflecting a year-over-year increase of 3.40%[128]. - The company reported a total revenue of 900 million in the latest fiscal year, reflecting a growth rate of 2.97% compared to the previous year[129]. - The company reported a revenue of 3.00 billion CNY for the year, representing a 4.00% increase compared to the previous year[130]. Dividend Policy - The company plans to distribute a cash dividend of CNY 0.95 per 10 shares, with a capital reserve conversion of 7 shares for every 10 shares held[5]. - The cash dividend for 2019 represents 21.04% of the net profit attributable to ordinary shareholders, which is RMB 39,130,702.48[88]. - The total cash dividend for 2019, including other methods, is RMB 8,233,650.00, which constitutes 100% of the total distributable profit[88]. - The cash dividend distribution is scheduled to be implemented on June 18, 2019[90]. - The company has maintained a consistent cash dividend payout ratio over the past three years, with ratios of 20.54% in 2017, 20.48% in 2018, and 21.04% in 2019[88]. - The company has implemented a profit distribution policy and a three-year shareholder return plan[135]. - The company reported a total cash dividend distribution of 7.36695 million yuan for the 2018 fiscal year[135]. Research and Development - The company has invested in the development of new technologies, including enteric-coated gelatin capsules, and has received multiple patents for its innovations[30]. - The company plans to enhance its R&D investment to strengthen its competitive advantage in the pharmaceutical supply industry[31]. - The company’s R&D efforts led to the acquisition of 2 utility model patents and 18 technical innovations during the year[37]. - Research and development expenses amounted to 12,774,858.80 yuan, accounting for 3.92% of operating revenue[54]. - Research and development investments have increased by 14% compared to the previous year, aimed at innovation[128]. - The company has a strong focus on research and development, particularly in the area of plant-based capsules[173]. Market Expansion and Strategy - The company has a stable customer base across over 30 provinces in China, benefiting from the increasing demand for pharmaceuticals and health products[29]. - The company is focused on expanding its market presence through customized marketing services and technical support for clients[29]. - The company plans to optimize its management system, enhance talent acquisition, and implement performance assessment for management levels to improve operational efficiency[77]. - The company aims to reduce costs by setting specific targets for each department to decrease expenses and improve budget management, thereby minimizing resource waste[78]. - The company is committed to market-oriented strategies, including developing new markets and clients, enhancing customer service, and leveraging its technical advantages in traditional Chinese medicine and enteric-coated capsules[78]. - The company plans to expand its market presence by introducing new products and technologies in the upcoming quarters[128]. - Market expansion plans include entering three new provinces in China, aiming to increase market share by 10% in these regions[98]. - The company is considering strategic acquisitions to bolster its product line, with a budget of 200 million CNY earmarked for potential mergers and acquisitions[99]. Operational Efficiency - The company has implemented a centralized procurement model to optimize costs and ensure a steady supply of materials[25]. - The company completed 25 technical improvement projects during the reporting period, enhancing production capacity and efficiency[37]. - The company has implemented new strategies to enhance operational efficiency, targeting a 5% reduction in production costs over the next year[96]. - The company has implemented cost-control measures that are expected to improve profitability margins in the next quarter[128]. - The company has established a comprehensive performance evaluation system and provides regular health check-ups for employees[136]. Risk Management - The company has outlined potential risks and countermeasures in its future development outlook, emphasizing the importance of investor awareness regarding investment risks[5]. - The company faces risks from regulatory changes in the pharmaceutical industry, including policies like "volume-based procurement" and "consistency evaluation," which may impact product pricing and market competition[79]. - Fluctuations in raw material prices, particularly for gelatin used in capsules, pose a risk to procurement costs and overall profit margins, necessitating strategic supplier management[79]. - The COVID-19 pandemic has impacted the company's operations, prompting proactive measures to mitigate adverse effects on production and business continuity[80]. Corporate Governance - The company has established a governance structure that complies with relevant laws and regulations, holding 3 shareholder meetings and 4 board meetings during the reporting period[185]. - The company maintains independence from its controlling shareholders in terms of assets, personnel, finance, and operations, ensuring a complete business system[187]. - The company has an independent financial department with a complete accounting system, allowing for autonomous financial decision-making[190]. - The company has established a commitment from major shareholders to avoid any competition with the company, ensuring a conflict-free operational environment[192]. - The company has received seven national invention patents in recent years, including various types of hollow capsules[173]. - The company has a diverse board with members holding various professional backgrounds, including finance, law, and management[166][167][168][169][170]. Environmental and Social Responsibility - The company has invested in upgrading its coal-fired boiler to a gas boiler to achieve energy conservation and emission reduction[136]. - The company donated 233,600 yuan to social welfare and participated in various community service activities[137]. - The company adheres to environmental protection regulations and has set up a unified management system for its environmental efforts[136]. - The company and its subsidiaries are not classified as key pollutant discharge units by environmental protection authorities[141]. Shareholder Information - A total of 45,130,000 restricted shares were released and became tradable on October 25, 2019, following the expiration of the lock-up period[145]. - The total number of shares after the release of restricted shares is 86,670,000, with 52.07% being restricted shares and 47.93% being unrestricted shares[146]. - The company had 14,819 shareholders at the end of the reporting period, compared to 13,825 at the end of the previous month[151]. - The largest shareholder, Yu Chunming, holds 40.05% of the shares, totaling 34,710,000 shares, with a decrease of 440,000 shares during the reporting period[152]. - The company did not engage in any repurchase transactions during the reporting period[153]. - The company has not undergone any changes in its major shareholders or actual controllers in the past year[156].

Financial Performance - Operating revenue for the reporting period was ¥80,435,444.35, representing a year-on-year increase of 22.59%[8] - Net profit attributable to shareholders of the listed company was ¥12,999,710.68, marking a significant increase of 57.80% compared to the same period last year[8] - The basic earnings per share rose to ¥0.15, a 50.00% increase from the previous year[8] - The total comprehensive income attributable to the parent company was ¥12,999,710.68, an increase of 57.5% from ¥8,238,006.99 in the previous year[41] - The company's total profit for the year-to-date period was ¥35,150,177.13, compared to ¥32,368,511.40 in the previous year, reflecting a growth of 8.7%[46] - Net profit for Q3 2019 reached ¥32,674,206.11, up 9.4% from ¥29,905,725.12 in Q3 2018[49] Assets and Liabilities - Total assets at the end of the reporting period reached ¥800,722,844.59, an increase of 2.65% compared to the previous year[8] - Total liabilities decreased from CNY 83,445,188.64 to CNY 80,979,152.33[29] - The company's total assets as of September 30, 2019, amounted to CNY 801,249,215.61, compared to CNY 777,509,052.22 at the end of 2018, indicating a growth of 3.0%[35] - Current assets totaled CNY 526,413,397.42, an increase of 6.4% from CNY 494,876,819.90 at the end of 2018[33] - The total liabilities of the company decreased slightly to CNY 81,427,008.69 from CNY 82,994,101.41, a reduction of 1.9%[34] Cash Flow - The net cash flow from operating activities was ¥16,239,442.96, a decrease of 17.77% compared to the previous year[8] - Cash flow from operating activities was ¥30,274,791.76, an increase of 14.5% compared to ¥26,416,289.88 in the same quarter last year[53] - Net cash flow from operating activities decreased to CNY 32,674,782.77, down 10.5% from CNY 36,538,288.17 in the previous period[55] - The total cash inflow from investment activities was ¥377,885,408.48, down from ¥391,669,378.06 in the previous year[53] - The company incurred a net cash outflow from investment activities of ¥32,024,049.15, compared to a net inflow of ¥162,356,804.57 in the same period last year[53] Shareholder Information - The total number of shareholders at the end of the reporting period was 13,534[12] - The top shareholder, Yu Chunming, holds 40.56% of the shares, with 25,000,000 shares pledged[12] Research and Development - Research and development expenses increased by CNY 2,776,900, a growth of 42.57%, due to increased R&D investment[16] - Research and development expenses for the third quarter of 2019 were CNY 2,629,362.68, up from CNY 1,851,921.18, reflecting a growth of 42.0%[37] - Research and development expenses increased to ¥7,831,637.11, up 21.6% from ¥6,442,022.37 in Q3 2018[49] Other Financial Metrics - The weighted average return on equity was 1.82%, up from 1.24% in the previous year[8] - The company reported non-recurring gains of ¥4,100,348.48 during the reporting period[10] - Other income decreased by CNY 2,837,300, a decline of 52.52%, mainly due to a reduction in government subsidies received[16] - The company reported a financial income of ¥5,642,071.95 for the year-to-date period, slightly down from ¥5,648,765.60 in the previous year[44]

Financial Performance - The company's operating revenue for the first half of 2019 was RMB 156,388,560.75, representing a 6.83% increase compared to RMB 146,387,310.91 in the same period last year[17]. - The net profit attributable to shareholders of the listed company decreased by 10.72% to RMB 18,396,793.94, down from RMB 20,606,571.02 in the previous year[17]. - The basic earnings per share decreased by 12.50% to RMB 0.21, down from RMB 0.24 in the previous year[17]. - The company reported a net profit increase, with retained earnings rising to CNY 284,840,251.85 from CNY 272,970,324.96, an increase of approximately 4.3%[127]. - The company reported a total profit of CNY 20,506,698.23 for the first half of 2019, down from CNY 23,367,319.91 in the first half of 2018[130]. - The company reported a total comprehensive income of 21,302,624.19 for the current period[158]. Cash Flow - The net cash flow from operating activities increased significantly by 110.54%, reaching RMB 14,035,348.80, compared to RMB 6,169,477.76 in the same period last year[17]. - Cash flow from operating activities surged by 110.54% to RMB 14,035,348.80, mainly due to increased cash receipts from sales and services[38]. - The net cash flow from investment activities was CNY 22,996,574.86, down from CNY 168,074,178.17 in the first half of 2018, indicating a decrease of 86.3%[140]. - The net cash flow from financing activities was negative at CNY -6,765,654.86, worsening from CNY -2,493,394.65 in the first half of 2018[140]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 780,491,315.27, a slight increase of 0.06% from RMB 780,034,833.48 at the end of the previous year[17]. - Total liabilities decreased to CNY 73,278,804.46 from CNY 83,445,188.64, representing a reduction of approximately 12.8%[122]. - The total owner's equity at the end of the current period was 707 million yuan, showing a slight increase from the previous period's 703 million yuan[148]. Research and Development - Research and development expenses increased by 42.80% to RMB 6,671,439.67, primarily due to increased investment in R&D activities[38]. - The company is investing 100 million CNY in R&D for new technologies over the next two years, focusing on sustainable production methods[72]. - The company is focusing on enhancing its research and development capabilities to innovate new technologies and products[148]. Market Strategy and Expansion - The company is actively expanding its market presence and developing new products, including enteric-coated gelatin capsules[31]. - The company plans to expand its market presence by entering two new provinces in China by the end of 2019, aiming for a 30% increase in market share[75]. - A strategic acquisition of a smaller competitor is in progress, which is projected to enhance the company's product portfolio and increase annual revenue by 5%[71]. Quality and Compliance - The company has established a complete quality management system, complying with GMP standards and has obtained FDA DMF registration for its products[29]. - The company has received multiple certifications, including ISO 9001:2015 and ISO 14001:2015, ensuring high-quality production and environmental management[29]. - The company faces regulatory risks due to the lack of a robust management system in the pharmaceutical capsule industry, which may lead to market irregularities and quality discrepancies among products[61]. Shareholder Returns - The company plans not to distribute cash dividends or issue bonus shares during this reporting period[6]. - The company has committed to maintaining a dividend payout ratio of 30% of net profits, ensuring returns to shareholders[74]. Challenges and Risks - The company has faced challenges in achieving expected benefits due to market competition and policy impacts, leading to a decrease in product sales prices[51]. - The main raw material, gelatin for capsules, is subject to significant price fluctuations, which could impact procurement costs and gross margins if prices rise sharply[62]. - The company is at risk of product price reductions due to intensified competition from policies like "4+7" volume-based procurement, which may affect profitability[62]. Corporate Governance - The company has not experienced any significant changes in project feasibility during the reporting period[55]. - The company has not disclosed any important information regarding its controlling or participating companies during the reporting period[59]. - The company has not faced any penalties or rectification issues during the reporting period[83]. Financial Reporting - The half-year financial report has not been audited[79]. - The financial statements were approved for external reporting by the company's board of directors on August 27, 2019[160]. - The company adheres to the enterprise accounting standards, ensuring the financial statements reflect its financial status accurately[164].